Device Trial Radar · NCT05898074
Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 9, 2023
Primary completion
Dec 15, 2026
Study completion Feb 15, 2027
Sponsor
- Lead sponsor
- Indiana UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- 3-D Matrix UK Ltd.
- First posted
- Jun 12, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to specifically evaluate the effectiveness of PuraGel, a RADA16 polypeptide hydrogel, in expediting post-operative healing and re-mucosalization of the nasoseptal flap harvest site during endoscopic skull base surgery and the impact on patient and sinonasal morbidity.
Conditions
- Skull Base Neoplasms
- Cerebrospinal Fluid Leakage
- Nasal; Hypertrophy, Mucous Membrane (Septum)
Interventions
Non-Absorbable Packing (Silastic Splint)Device
Participant will have silastic splint applied to nasoseptal flap harvest site
PuraGel (RADA16) HydrogelDevice
Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Modified Lund-Kennedy nasal endoscopy scoreTime frame: 1 week, 4 weeks, and 12 weeks following surgery.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Indiana University
Indianapolis, Indiana · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.